Compare Citius Pharmaceuticals Inc (CTXR) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Exxon Mobil Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Exxon Mobil Corporation trades at $168.94 (market cap $692.86B). The key difference: Exxon Mobil Corporation is far larger — about 50870.8× Citius Pharmaceuticals Inc's market cap, and Exxon Mobil Corporation pays a 2.45% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Exxon Mobil Corporation for 99 Days on average.
| CTXR | XOM | |
|---|---|---|
Market Cap | $13.62M | $692.86B |
Volume | 132,438 | 13,225,996 |
Sector | Health | Energy |
52-Week High | $1.82 | $171.52 |
52-Week Low | $0.48 | $110.64 |
Typical Hold Time | 17 Days | 99 Days |
Enterprise Value | $3.79M | $724.64B |
Dividend Yield | — | 2.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4887, down 3.84% in the last session, with a bearish technical signal from moving averages but bullish oscillators. The company reported $7.1M revenue for the first nine months of fiscal 2026 from LYMPHIR sales, yet net losses persist, with a net income margin of -651.27%. Cash flow remains positive due to financing activities, and analyst consensus is strongly bullish with five buy ratings.
The outlook hinges on commercial execution of LYMPHIR, offering growth potential amid high losses. Key risks include sustained negative profitability, cash burn, and competitive pressures. Investors should weigh the speculative growth narrative against fundamental weaknesses.
Exxon Mobil (XOM) trades at $168.56, up 2.74% today, with a bullish technical signal from moving averages and a consensus analyst price target of $166.67. Recent earnings show mixed results, with a Q2 2026 miss but beats in prior quarters. Revenue has declined from $398.7B in 2022 to $323.9B in 2025, though 2026 projects a rebound to $361.1B. News highlights potential investment in Venezuela's oil fields and expansion in Guyana and the Permian Basin.
XOM presents a stable investment with a 12.55% ROE and dividend yield, but faces risks from volatile oil prices and geopolitical ventures. Analyst sentiment is mixed with 36.36% buy ratings, indicating cautious optimism amid execution risks and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
